| Nagy & Majestro, D.d.s., Inc. | |
|
Main Street Chapmanville Prog Bldg Suite #7 Champmanville WV 25508-4541 | |
| (304) 855-3939 | |
| (304) 855-5939 |
| Full Name | Nagy & Majestro, D.d.s., Inc. |
|---|---|
| Speciality | Dentist |
| Location | Main Street, Champmanville, West Virginia |
| Authorized Official Name and Position | Philip M Majestro (VICE-PRESIDENT) |
| Authorized Official Contact | 3048553939 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Nagy & Majestro, D.d.s., Inc. Po Box 4541 Chapmanville WV 25508-4541 Ph: (304) 855-3939 | Nagy & Majestro, D.d.s., Inc. Main Street Chapmanville Prog Bldg Suite #7 Champmanville WV 25508-4541 Ph: (304) 855-3939 |
| NPI Number | 1346328390 |
|---|---|
| Provider Enumeration Date | 11/01/2006 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346328390 | NPI | - | NPPES |
| 0134112000 | Medicaid | WV | |
| 0013026000 | Medicaid | WV | |
| 0134101000 | Medicaid | WV | |
| 133353 | Other | UNITED CONCORDIA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 3193 (West Virginia) | Secondary |
| 122300000X | Dentist | 3130 (West Virginia) | Primary |
News Archive
Children's Hospital Boston and eClinicalWorks(R) today announced a collaboration that will enable patients who are seen at Children's ambulatory programs and in primary care practices in the Pediatric Physicians' Organization at Children's (PPOC) to aggregate health data from both sites of care into a single personally controlled health record (PCHR).
Young Swedish men are consuming at least double the recommended amount of salt according to a study carried out by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital.
A multi-institutional team of Boston-area researchers has discovered a chemical that works in mice to kill the rare but aggressive cells within breast cancers that have the ability to seed new tumors.
Genzyme Corporation and Arecor Limited today signed an agreement providing for extensive collaboration on developing advanced formulations for protein therapeutics. The agreement provides for a close working relationship between Genzyme and Arecor in developing stable, high strength formulations of labile biomolecules. This agreement is the result of a two year working relationship where Arecor has demonstrated their technologies offer an improvement over conventional approaches in protein formulation.
Are you a social media enthusiast or simply a Facebook addict? Researchers from Norway have developed a new instrument to measure Facebook addiction, the Bergen Facebook Addiction Scale.
› Verified 3 days ago